Overheard on Twitter
Twitter updates from Selventa / Selventa.
Updated: 33 min 28 sec ago
Selventa: To fight metastasis, maybe we need to knock this SOX4 off! http://t.co/XkY9u7O24E
Selventa: To fight metastasis, maybe we need to knock this SOX4 off!
http://t.co/XkY9u7O24E
Selventa: Your fat cells are MUSE-ing. Why fat cells can be awesome! http://t.co/rpdUm3OAc8
Selventa: Your fat cells are MUSE-ing. Why fat cells can be awesome! http://t.co/rpdUm3OAc8
Selventa: Watch David de Graaf's presentation on Selventa's Systems Diagnostics: http://t.co/6jXOgW9KXV
Selventa: Watch David de Graaf's presentation on Selventa's Systems Diagnostics: http://t.co/6jXOgW9KXV
Selventa: How good is your "second genome"? http://t.co/FmGfTZipGt
Selventa: How good is your "second genome"? http://t.co/FmGfTZipGt
Selventa: Exciting immunotherapies in the near future for cancer. However, will the high price tag create trouble? http://t.co/oIoYeH84Xa
Selventa: Exciting immunotherapies in the near future for cancer. However, will the high price tag create trouble? http://t.co/oIoYeH84Xa
Selventa: RT @ASCO: Thousands of slides from #ASCO13 have been added to #ASCOU in the last few days. Browse for free @ http://t.co/78vQkwimMB
Selventa: RT @ASCO: Thousands of slides from #ASCO13 have been added to #ASCOU in the last few days. Browse for free @ http://t.co/78vQkwimMB
Selventa: RT @Novartis: What do you hope to learn at #ASCO13 this year? We are particularly interested in new #advancedBC data
Selventa: RT @Novartis: What do you hope to learn at #ASCO13 this year? We are particularly interested in new #advancedBC data
Selventa: PatientsLikeMe Seeks Participation in New Open Research Exchange Platform http://t.co/M9zuyKvXbv
Selventa: PatientsLikeMe Seeks Participation in New Open Research Exchange Platform http://t.co/M9zuyKvXbv
Selventa: @jolaven - @selventa would like to learn more about Baystate Health's ACO initiatives
Selventa: @jolaven - @selventa would like to learn more about Baystate Health's ACO initiatives
Selventa: 2 drugs (Tafinlar for BRAF V600E and Mekinist for V600E or V600K) FDA approved as single agents for melanoma w/ BioMerieux THxID BRAF test
Selventa: 2 drugs (Tafinlar for BRAF V600E and Mekinist for V600E or V600K) FDA approved as single agents for melanoma w/ BioMerieux THxID BRAF test
Selventa: Selventa's HR Director, Hewan Small selected into a Mass Biotech Council advisory group. http://t.co/PcyewcqgwP
Selventa: Selventa's HR Director, Hewan Small selected into a Mass Biotech Council advisory group. http://t.co/PcyewcqgwP
Selventa: Get excited about #ASCO13. http://t.co/euCPzknv1B
Selventa: Get excited about #ASCO13. http://t.co/euCPzknv1B
Selventa: Selventa's presentation - A single biomarker panel predicts response to infliximab in patients with IBD - at #DDW2013 received well
Selventa: Selventa's presentation - A single biomarker panel predicts response to infliximab in patients with IBD - at #DDW2013 received well
Selventa: RT @genentech: Sandra Horning Head of Oncology #Genentech shares her #ASCO13 story. From academia to ASCO prez to patient & survivor http:/…
Selventa: RT @genentech: Sandra Horning Head of Oncology #Genentech shares her #ASCO13 story. From academia to ASCO prez to patient & survivor http:/…
Selventa: FDA approves Simponi for UC. http://t.co/E36PHplBk6
Selventa: FDA approves Simponi for UC. http://t.co/E36PHplBk6
Selventa: Tarceva. Approved for 1st line with CDx (for selected NSCLC patients with EGFR exon 19 del or exon 21 mut). http://t.co/sYaodRV44u
Selventa: Tarceva. Approved for 1st line with CDx (for selected NSCLC patients with EGFR exon 19 del or exon 21 mut). http://t.co/sYaodRV44u
Selventa: Read about Selventa's 2013 NA Frost & Sullivan Technology Leadership Award for Systems Diagnostics - http://t.co/1pHSuVN7Ew
Selventa: Read about Selventa's 2013 NA Frost & Sullivan Technology Leadership Award for Systems Diagnostics - http://t.co/1pHSuVN7Ew
Selventa: Frost & Sullivan recognizes Selventa with a 2013 North America F&S Technology Leadership Award. http://t.co/9oWVa3uHXu
Selventa: Frost & Sullivan recognizes Selventa with a 2013 North America F&S Technology Leadership Award. http://t.co/9oWVa3uHXu
Selventa: Healthcare reform underscores the need to engage patients and advocacy groups early. http://t.co/4UVWXUBPKO
Selventa: Healthcare reform underscores the need to engage patients and advocacy groups early. http://t.co/4UVWXUBPKO
Selventa: Lumena pharma secures $23M in Series A to clinically develop a lead product for cholestatic liver disease treatment. http://t.co/zva87CKgsd
Selventa: Lumena pharma secures $23M in Series A to clinically develop a lead product for cholestatic liver disease treatment. http://t.co/zva87CKgsd